All In Biotech

Drug Trial Radar · NCT00531479

Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

A Prospective, Randomized Trial Comparing The Efficacy Of Anidulafungin And Voriconazole In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Proven Or Probable Invasive Aspergillosis

Last checked: Nov 19, 2026Latest source record: Apr 30, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 459 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

459

Actual

Start

Jul 2008

Primary completion

Apr 2011

Study completion May 2011

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 18, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compares the effectiveness and safety of the combination of anidulafungin and voriconazole compared to that of voriconazole alone (which is generally considered the standard of care) for the treatment of Invasive Aspergillosis.

Conditions

  • Aspergillosis

Interventions

  • voriconazoleDrug

    First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV BID plus anidulafungin placebo IV qd. Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin placebo IV qd. Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin placebo IV qd, OR Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy. Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.

  • anidulafunginDrug

    First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter. Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd. Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd, OR Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy. Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.

  • voriconazoleDrug

    First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter. Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd. Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd, OR Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy. Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause Mortality at Week 6 in Participants With Proven or Probable Invasive AspergillosisTime frame: Day 1 to Day 42 (Week 6)

Locations

107 sites in 24 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Little Rock, Arkansas

  • Pfizer Investigational Site

    La Jolla, California

  • Pfizer Investigational Site

    La Jolla, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    San Francisco, California

  • Pfizer Investigational Site

    Gainesville, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Atlanta, Georgia

  • Pfizer Investigational Site

    Chicago, Illinois

  • Pfizer Investigational Site

    Chicago, Illinois

  • Pfizer Investigational Site

    Baltimore, Maryland

  • Pfizer Investigational Site

    Baltimore, Maryland

  • Pfizer Investigational Site

    Baltimore, Maryland

  • Pfizer Investigational Site

    Baltimore, Maryland

  • Pfizer Investigational Site

    Detroit, Michigan

  • Pfizer Investigational Site

    Detroit, Michigan

  • Pfizer Investigational Site

    Rochester, New York

  • Pfizer Investigational Site

    Chapel Hill, North Carolina

  • Pfizer Investigational Site

    Winston-Salem, North Carolina

  • Pfizer Investigational Site

    Portland, Oregon

  • Pfizer Investigational Site

    Philadelphia, Pennsylvania

  • Pfizer Investigational Site

    Houston, Texas

  • Pfizer Investigational Site

    Seattle, Washington

  • Pfizer Investigational Site

    Seattle, Washington

  • Pfizer Investigational Site

    Westmead, New South Wales, Australia

  • Pfizer Investigational Site

    Herston, Queensland, Australia

  • Pfizer Investigational Site

    Adelaide, South Australia, Australia

  • Pfizer Investigational Site

    Bruges, Belgium

  • Pfizer Investigational Site

    Brussels, Belgium

  • Pfizer Investigational Site

    Leuven, Belgium

  • Pfizer Investigational Site

    Yvoir, Belgium

  • Pfizer Investigational Site

    Curitiba, Paraná, Brazil

  • Pfizer Investigational Site

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Pfizer Investigational Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Pfizer Investigational Site

    Winnipeg, Manitoba, Canada

  • Pfizer Investigational Site

    Winnipeg, Manitoba, Canada

  • Pfizer Investigational Site

    Hamilton, Ontario, Canada

  • Pfizer Investigational Site

    Hamilton, Ontario, Canada

Showing 40 of 107 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.